CP38: Fluorescent Cyclic Peptide Antitumor Activity and Transcriptomic Data

Research data from figshare details the synthesis and antitumor mechanism of a fluorescent cyclic peptide, CP38, targeting integrin αvβ3 on hepatocellular carcinoma. The dataset, authored by Zhiqin Zhang and last updated in April 2026, includes cytotoxicity measurements with IC50 values of 6.39 and 10.78 μM for specific cell lines and an in vivo tumor inhibition rate of 80.5%. Transcriptomic analysis indicates the peptide's effects are associated with the cancer proteoglycans and TNF signaling pathway.

Use Cases

• Validate drug candidate cytotoxicity based on reported IC50 values for MHCC97H and HCCLM3 cell lines.
• Model integrin αvβ3 targeting mechanisms using the described peptide structure and selectivity data.
• Analyze transcriptomic pathway regulation associated with the cancer proteoglycans and TNF signaling pathway.
• Compare in vivo therapeutic efficacy against a standard like sorafenib using the reported 80.5% tumor inhibition rate.

Strengths

• Includes specific, quantitative bioactivity results (IC50 values of 6.39 and 10.78 μM).
• Reports a concrete in vivo efficacy metric (80.5% tumor inhibition rate).
• Links mechanistic action to specific molecular pathways (PI3K/Akt/mTOR, cancer proteoglycans, TNF).

Limitations

• Dataset is very small (1.4 KB), indicating limited scope.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

figshare

Collection Method

Likely contains experimental results from peptide synthesis, cell culture assays, and transcriptomic analysis.

Freshness

Last updated 2026-04-18 13:33:22; freshness should be verified.